Hand一代
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether a new drug is safe and works for people with a type of lymphoma that has not improved with usual treatment. Participating may give you access to a new option if standard therapies have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-Hodgkin lymphoma, a cancer of the immune system.
- Your lymphoma has not responded to or has come back after standard treatment.
- You are able to attend study visits and follow the treatment plan.
- You are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
This study tests whether a type of immune cell therapy called CIK cells is safe and feasible for people with early-stage liver cancer who have just had their tumor removed. It aims to see if this treatment can help prevent the cancer from coming back.
This trial tests a new type of immunotherapy called CAR-T cells that are specially designed to find and attack your cancer cells. It is for people with certain blood cancers that have not improved with standard treatments, and it may give you another option when others have not worked.
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.